PharmaFocus Today – Page 17 – media

Can 3 cents produce a piece of aspirin?

Recently, after the announcement of the proposed winning results of the 10th national centralized drug procurement, the centralized procurement price of 3 cents a piece of aspirin attracted national attention as a “low price”. The public’s concern is largely due to the concern about whether the clinical efficacy of the drug can be guaranteed at a low price. So, can 3 cents produce a piece of qualified aspirin? ▍3 cents can produce The answer is yes. “This price can be achieved through large-scale production. Since the raw materials of aspirin itself are relatively cheap and the excipients are not particularly expensive, if the equipment conditions are good and the output is large, its cost will also be reduced. It does not mean that when the price drops to a certain level, the product quality will be low and the company will cheat. This is a commercial behavior. The company takes ...
- Source: drugdu
- 105
- December 20, 2024
Kanghua Biotech’s Recombinant Norovirus Vaccine (Pichia pastoris) Approved for Clinical Trials

On December 17, Kanghua Biotech (300841) announced that its hexavalent recombinant Norovirus vaccine (Pichia pastoris) has received a clinical trial approval notification. The vaccine developed by the company has recently been issued a “Clinical Trial Approval Notification” by the National Medical Products Administration, granting permission to conduct clinical trials. This vaccine is intended to prevent Norovirus infections and the acute gastroenteritis they cause, with the theoretical ability to prevent over 90% of related infections. The receipt of the clinical trial approval notification will not have a significant impact on the company’s short-term financial status and operating performance. The company will actively promote clinical research for this product; if successful, it will enrich the company’s product portfolio, enhance its core competitiveness and market position, thereby increasing profitability. However, the vaccine development process is lengthy and technically challenging, posing certain research risks and uncertainties that investors should consider cautiously. In the first ...
- Source: drugdu
- 102
- December 20, 2024
Can small molecule drugs achieve a breakthrough?

Wet age-related macular degeneration (Wet AMD) is the main cause of visual dysfunction and blindness in the elderly. Currently, intravitreal injection of anti-VEGF drugs has become the first-line treatment for the disease, but current anti-VEGF drugs still have many shortcomings, such as frequent injections with multiple potential risks, insensitive reactions in some patients, and low patient compliance. Therefore, it is urgent to find new therapeutic drugs. With the deepening of the understanding of pathological mechanisms, the emergence of multi-target small molecule drugs has opened up a new path for the treatment of this disease. Compared with the traditional approach of only inhibiting VEGF, these small molecules are expected to provide new opportunities for improving efficacy, reducing treatment burden and delaying drug resistance by intervening in multiple links such as angiogenesis, inflammation and oxidative stress. AMD, The third leading cause of blindness worldwide Age-related macular degeneration (AMD) is an age-related, chronically ...
- Source: drugdu
- 152
- December 20, 2024
China Biopharmaceuticals and Sinopharm Holdings sign strategic cooperation agreement

On December 13th, China Biopharmaceutical and Sinopharm Group signed a deep strategic cooperation agreement in Chengdu. The two sides will fully integrate the resources of Sinopharm Group’s National University Pharmacy, SPS+professional pharmacy, and China Biopharmaceutical’s rich product resources, and carry out deep cooperation in the off hospital market to jointly build a nationwide retail network and improve the convenience of patients’ drug purchases. President Lian Wanyong and Vice President Wu Yijian of China National Pharmaceutical Group, CEO of China Biopharmaceutical and Chairman of CP Tianqing Xie Chengrun, Vice President of CP Tianqing Chen Hui, and others attended the signing ceremony. Liu Tianyao, General Manager of the Global Procurement and Supply Chain Service Center of China National Pharmaceutical Group, and Qi Tianze, Special Assistant to the Chairman of CP Tianqing, signed the agreement on behalf of both parties. The heads of various business units of China Biopharmaceutical and some subsidiaries of ...
- Source: drugdu
- 90
- December 19, 2024
Ed Biotech forges a precise medical “compass”

Ed Biotech has always focused on research and innovation, steadily moving forward on the path of precise diagnosis of tumors, allowing precision medical products to better play the role of a “compass” and alleviate patients’ pain. Recently, a reporter from Shanghai Securities News came to the Xiamen headquarters of Ed Biotech to listen to their stories of forging ahead and helping China’s precision medicine industry rise to new heights. Take the difficult yet correct path Xiamen Haicang District, Aide Biological Dust free Production Workshop. We can produce 30 types of Class III diagnostic products here, with a daily production capacity of over 100000 people. These products cover various types of cancer with precision medical conditions, and most of them are domestically approved, some of which are even internationally pioneering. When the reporter met with the company’s general manager Luo Jiemin, this “post-80s” PhD had just returned from the academic annual ...
- Source: drugdu
- 105
- December 19, 2024
Two innovative medical devices have been approved for market launch

Recently, the National Medical Products Administration approved the registration applications for two innovative products, the “Proton Therapy System” of Maisheng Medical System Company (hereinafter referred to as Maisheng Medical) and the “Cardiac Pulse Electric Field Ablation Device” of Shanghai Hongtong Industrial Co., Ltd. (hereinafter referred to as Shanghai Hongtong). Maisheng Medical, the first product to be launched in China Maisheng Medical was founded in 2004 and is headquartered in Littleton, Greater Boston, Massachusetts, USA. We specialize in the research, development, production, installation, and service of miniaturized proton therapy equipment for cancer treatment, with branch structures in Europe and Asia. We are a leader in the field of miniaturized proton therapy. The miniaturized proton radiotherapy system developed based on its own core technology has unique advantages such as good clinical efficacy, high integration level, small footprint, and low overall customer ownership cost. At present, Maisheng Medical has advanced proprietary intellectual property ...
- Source: drugdu
- 94
- December 19, 2024
5 innovative medical devices enter special review process

On December 16th, the National Medical Products Administration’s Device Review Center released the results of the special review application for innovative medical devices (No. 11 of 2024), intending to approve 5 innovative medical device projects to enter the special review process. 1. Hot steam ablation system: Shanghai Lixiao Medical Technology Co., Ltd Lixiao Medical was founded in January 2019 by Dr. Cheng Lifei, Global Vice President of Business Development at Medtronic. It is an innovative medical technology platform that focuses on the introduction of advanced medical technologies from overseas, local research and development, and industrialization. It specializes in the research and development of medical devices for the treatment of chronic diseases such as cardiovascular, urinary, and respiratory diseases. As of now, Lixiao Medical has completed two rounds of financing of nearly one billion US dollars, led by well-known investment institutions such as Eli Lilly Asia, Sequoia Capital, and WuXi AppTec. ...
- Source: drugdu
- 98
- December 19, 2024
The two weight loss giants were launched on the same day on Meituan. Has the new battle begun?

The battle between the two weight loss giants has officially entered the deep water period. From clinical PK to production capacity competition, to the future layout competition, Novo Nordisk and Eli Lilly are fighting fiercely. With the advancement of the commercialization of the two giants in China, the new battle has surfaced. On December 9, the oral version of semaglutide was launched on Meituan’s entire network, and at the same time, the reservation service for telpotide was also opened. The first confrontation between the two parties in the Chinese market has once again attracted widespread attention from the market. This indicates that we can no longer use the perspective of traditional medicine to view GLP-1R drugs that are increasingly closely integrated with consumer medicine. That is, traditional channels such as pharmacies are certainly very critical, but online channels are also becoming more and more indispensable. Otherwise, Eli Lilly would not ...
- Source: drugdu
- 99
- December 19, 2024
long-acting AIDS prevention drugs rank first

On December 12, 2024, the top ten scientific breakthroughs of the year in Science magazine arrived as expected. An AIDS drug, Lenacapavir, was named the top scientific breakthrough of the year. The drug only needs to be injected once every 6 months and has achieved remarkable success in preventing HIV infection, which is expected to help end the HIV/AIDS epidemic. The interim analysis data of the key Phase 3 clinical trial released by Gilead Sciences showed that twice-yearly dosing achieved 100% AIDS prevention effect in women. On June 20, 2024, Gilead Sciences announced the interim analysis results of its key Phase 3 clinical trial of Lenacapavir, an AIDS prevention drug, showing that only twice-yearly dosing achieved 100% AIDS prevention effect in women. It is reported that this project is the most comprehensive and diverse AIDS prevention trial project ever conducted. Dr. Merdad Parsey, Gilead’s Chief Medical Officer, said that two ...
- Source: drugdu
- 123
- December 19, 2024
From PROTAC to RIPTAC, it is a challenge and an opportunity

In 2001, Craig Crews, the former founder of Arvinas and Professor of Yale University, first proposed the concept of PROTAC, leading a new revolution in small molecule innovative drugs. In 2023, Professor Crews founded HALDA Therapeutics and unveiled their latest technology platform RIPTAC at the ASCO-GU conference. At the same time, he published the latest article on bioRxiv, describing the results of the RIPTAC proof-of-concept study. In 2024, HALDA Therapeutics announced the completion of a $126 million Series B financing, and emphasized that the funds raised will be used for clinical trials of two candidate drugs in patients with prostate cancer and breast cancer. From PROTAC to RIPTAC, it was originally an innovative theory proposed by the same professor, but it is essentially based on two different directions. The former emphasizes the transition from “placeholder-driven” to “event-driven”, while the latter returns from “event-driven” to “placeholder-driven”. What is the reason? More ...
- Source: drugdu
- 89
- December 19, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.